Cristofanilli, M. and Slamon, D.J. and Ro, J. and Bondarenko, I. and Im, S-A. and Masuda, N. and Colleoni, M. and DeMichele, A. and Loi, S. and Verma, S. and Iwata, H. and Harbeck, N. and Loibl, S. and Andre´, F. and Puyana Theall, K. and Huang, X. and Giorgetti, C. and Huang Bartlett, C. and Turner, N.C. (2018) Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER22) advanced breast cancer (ABC): Analyses from PALOMA-3. Annals of Oncology, Vol.29 (Sapp.8). viii708-viii708. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
|
Text
mdy424.009.pdf Download (81kB) | Preview |
Abstract
Background: Endocrine therapy (ET)–resistant ABC is dependent on cyclin dependent kinase (CDK) 4/6. In the prospective, randomized, double-blind, phase 3 PALOMA-3 study, the CDK4/6 inhibitor PAL in combination with FUL significantly improved progression-free survival (PFS) vs placebo (PBO)þFUL (median PFS, 11.2 vs 4.6 mo; absolute difference, 6.6 mo; hazard ratio [HR] 0.50 [95% CI, 0.40–0.62]; P < 0.000001). Here, we report OS analysis with a median follow up of 44.8 mo. Methods: HRþ/HER2– ABC (N ¼ 521) patients (pts) who had relapsed or progressed on prior ET were randomized 2:1 to PAL (125 mg/d orally, schedule 3/1) þ FUL (500 mg per standard of care) or PBOþFUL. Primary endpoint was investigator-assessed PFS
| Item Type: | Article |
|---|---|
| Subjects: | Oncology |
| Divisions: | Departments > Department of Oncology and Medical Radiology |
| Depositing User: | Елена Шрамко |
| Date Deposited: | 11 Oct 2019 09:56 |
| Last Modified: | 11 Oct 2019 09:56 |
| URI: | http://repo.dma.dp.ua/id/eprint/4357 |
Actions (login required)
 |
View Item |
